State Street Corp ownership in SNDX / Syndax Pharmaceuticals, Inc.

Syndax 製藥公司

US ˙ NasdaqGS ˙ US87164F1057

Security	SNDX / Syndax Pharmaceuticals, Inc.
Institution	State Street Corp
Latest Disclosed Ownership	4,596,552 shares
Ownership	5.30%

2026-02-09 - State Street Corp has filed an SCHEDULE 13G form with the Securities and Exchange Commission (SEC) disclosing ownership of 4,596,552 shares of Syndax Pharmaceuticals, Inc. (US:SNDX). This represents 5.3 percent ownership of the company. In their previous filing dated 2024-10-18 , State Street Corp had reported owning 3,770,826 shares, indicating an increase of 21.90 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2026-02-09	2026-02-09	13G	3,770,826	4,596,552	21.90	5.30	20.45
2024-10-18	2024-10-18	13G/A	5,016,224	3,770,826	-24.83	4.40	-25.55
2024-01-25	2024-01-25	13G/A	3,648,463	5,016,224	37.49	5.91	10.26
2023-02-06	2023-02-06	13G/A		3,648,463		5.36

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	4,430,076	-166,476	-3.62	103,487	7.16	0.0036
2026-02-13	2025-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	4,596,552	743,003	19.28	96,574	62.89	0.0032
2025-11-14	2025-09-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,853,549	410,797	11.93	59,287	83.88	0.0021
2025-08-14	2025-06-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,442,752	-528,980	-13.32	32,241	-33.92	0.0012
2025-05-15	2025-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,971,732	54,216	1.38	48,793	-5.79	0.0020
2025-02-14	2024-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,917,516	146,690	3.89	51,790	-28.65	0.0020
2024-11-14	2024-09-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,770,826	148,491	4.10	72,588	-2.39	0.0030
2024-08-14	2024-06-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,622,335	-1,197,259	-24.84	74,367	-35.17	0.0032
2024-05-15	2024-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	4,819,594	-196,630	-3.92	114,706	5.82	0.0051
2024-02-14	2023-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	5,016,224	1,415,576	39.31	108,401	107.34	0.0053
2023-11-14	2023-09-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,600,648	-553,413	-13.32	52,281	-39.87	0.0029
2023-08-14	2023-06-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	4,154,061	287,831	7.44	86,944	6.48	0.0046
2023-05-15	2023-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,866,230	217,767	5.97	81,655	-12.06	0.0046
2023-05-15	2022-12-31	13F/A-99	SYNDAX PHARMACEUTICALS	COM	87164F105	3,648,463	1,031,026	39.39	92,853	47.63	0.0055
2023-05-15	2022-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,648,463	1,031,026		92,853		0.0055
2022-11-15	2022-09-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	2,617,437	181,920	7.47	62,897	34.23	0.0040
2022-08-15	2022-06-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	2,435,517	55,180	2.32	46,859	13.27	0.0028
2022-05-16	2022-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	2,380,337	-99,867	-4.03	41,370	-23.80	0.0020
2022-02-14	2021-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	2,480,204	376,757	17.91	54,292	35.06	0.0026
2021-11-15	2021-09-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	2,103,447	-1,066,985	-33.65	40,197	-26.16	0.0021
2021-08-16	2021-06-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	3,170,432	516,961	19.48	54,436	-8.25	0.0029
2021-07-09	2021-03-31	13F/A-1	SYNDAX PHARMACEUTICALS	COM	87164F105	2,653,471	953,751	56.11	59,332	56.95	0.0034
2021-05-17	2021-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	2,653,471	953,751		59,332		0.0034
2021-02-16	2020-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	1,699,720	581,000	51.93	37,802	128.94	0.0023
2020-11-10	2020-09-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	1,118,720	645,600	136.46	16,512	135.48	0.0011
2020-08-14	2020-06-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	473,120	33,218	7.55	7,012	45.30	0.0005
2020-06-19	2020-03-31	13F/A-1	SYNDAX PHARMACEUTICALS	COM	87164F105	439,902	-633	-0.14	4,826	24.77	0.0004
2020-05-11	2020-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	439,902	-633		4,826		423.8200
2020-02-06	2019-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	440,535	24,971	6.01	3,868	24.61	0.0003
2019-11-14	2019-09-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	415,564	91,018	28.04	3,104	2.71	0.0002
2019-08-14	2019-06-30	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	324,546	81,628	33.60	3,022	137.02	0.0002
2019-05-15	2019-03-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	242,918	24,266	11.10	1,275	31.04	0.0001
2019-02-12	2018-12-31	13F	SYNDAX PHARMACEUTICALS	COM	87164F105	218,652	22,794	11.64	973	-38.53	0.0001
2018-11-09	2018-09-30	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	195,858	41,851	27.17	1,583	46.44	0.0001
2018-08-14	2018-06-30	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	154,007	24,066	18.52	1,081	-41.60	0.0001
2018-05-15	2018-03-31	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	129,941	13,651	11.74	1,851	81.65	0.0002
2018-02-14	2017-12-31	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	116,290	31,756	37.57	1,019	2.83	0.0001
2017-11-14	2017-09-30	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	84,534	3,207	3.94	991	-12.84	0.0001
2017-08-14	2017-06-30	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	81,327	20,106	32.84	1,137	35.20	0.0001
2017-05-15	2017-03-31	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	61,221	2,300	3.90	841	99.29	0.0001
2017-02-09	2016-12-31	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	58,921	3,599	6.51	422	-49.76	0.0000
2017-01-13	2016-09-30	13F/A-1	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	55,322	9,776	21.46	840	87.50	0.0001
2016-11-14	2016-09-30	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	55,322			840
2016-08-12	2016-06-30	13F	SYNDAX PHARMACEUTICALS	Common equity shares	87164F105	45,546	45,546		448		0.0000

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.